All relevant data are within the paper and its Supporting Information files.

Introduction {#sec005}
============

The Middle East and North Africa (MENA) region appears to have the highest prevalence of hepatitis C virus (HCV) worldwide \[[@pone.0121873.ref001], [@pone.0121873.ref002]\]. The highest national prevalence of HCV globally is found in Egypt (14.7%) \[[@pone.0121873.ref003], [@pone.0121873.ref004]\]. Questions remain as to the prevalence of HCV in the rest of North Africa and to what extent, if any, are this region's rates influenced by the large HCV reservoir in Egypt.

The Maghreb region of North Africa borders Egypt to the east. Geographically, the region encompasses Algeria, Libya, Mauritania, Morocco and Tunisia. The combined population of this region is approximately 88 million people \[[@pone.0121873.ref005]\], or over one-fifth of the population of MENA. Our objective in this study was to systematically review and synthesize all epidemiological data on HCV antibody prevalence and incidence among the different population groups in the Maghreb; and to estimate the national population-level HCV prevalence for each of its five countries. The study is conducted under the umbrella of the MENA HCV Synthesis Project; an ongoing effort to characterize HCV epidemiology in the MENA region. The ultimate goal of this project is to provide the empirical evidence necessary for policy makers and public health stakeholders to set the key research, policy, and programming priorities for the MENA region.

Methods {#sec006}
=======

Data Sources and Search Strategy {#sec007}
--------------------------------

We conducted a systematic review of the literature following the Preferred Reporting Items for Systematic Reviews and Meta-analyses (PRISMA) guidelines ([S1 Table](#pone.0121873.s001){ref-type="supplementary-material"}) \[[@pone.0121873.ref006]\]. The primary outcome measure of interest was HCV antibody prevalence (sero-prevalence) and incidence (sero-incidence) in the Maghreb region. A secondary outcome measure of interest was HCV RNA prevalence among HCV antibody positive patients.

Main data sources for this review were PubMed (Medline) and Embase databases. No language restrictions were imposed in either database. While our PubMed search had no year limit, we restricted the search in Embase to articles published after 1980. However, since HCV was discovered in 1989, no effect of this restriction on our results is expected. The search criteria utilized *MeSH/Emtree* terms in PubMed and Embase, respectively, and text terms. Full details of the search criteria are presented in [S1 Box](#pone.0121873.s002){ref-type="supplementary-material"}. We used broad search criteria to insure completeness. Additional sources of data were primarily obtained through the MENA HIV/AIDS Epidemiology Synthesis Project database \[[@pone.0121873.ref007], [@pone.0121873.ref008]\]. These included international organizations' reports and country-level reports.

Study Selection {#sec008}
---------------

All records found through PubMed and Embase were initially screened to remove duplicates. The title and abstract for the remaining records were screened by two investigators (FAF and YAM) for relevance. Any uncertainty was settled through consultation with members of the study team. All relevant and potentially relevant full-text articles on the sero-prevalence or sero-incidence of HCV in the Maghreb were identified and subsequently screened. Case series, case reports, and reviews were excluded. We only included studies with primary data in our analysis. Publications reporting the same data were considered duplicates and counted as one publication. The bibliographies of relevant reviews were compared to our records, and studies reporting prevalence or incidence, not initially identified or retrieved, were added to our study.

Data Extraction {#sec009}
---------------

Data from relevant records were abstracted by two investigators (FAF and YAM) for the following indicators: author, year of publication, year of study, country of study, study site, study design, sampling technique, population, sample size, sero-prevalence, RNA prevalence, incidence, and risk factors for HCV infection. Any disagreements were discussed and settled among the study team. Articles in French were abstracted by one author (GRM). Articles in Arabic were abstracted by two of the authors (FAF) and (LJA). Data was extracted from abstracts when the full-text was not available. Though articles identifying HCV risk factors were not specifically searched for, risk factor data was abstracted from relevant reports when available.

Data Synthesis {#sec010}
--------------

Studies were organized by country and by study population. Study population was divided into categories according to the perceived risk of acquiring HCV infection. Four categories were defined: 1) high risk groups consisting of people who inject drugs (PWID), dialysis patients, hemophiliacs, and multi-transfused patients, among others; 2) intermediate risk groups including diabetics, barbers and others potentially exposed to HCV at intermediate risk such as healthcare workers; 3) low risk groups representing the general population including blood donors, pregnant women, healthy adults, army recruits, and healthy controls from case-control studies, among others; and 4) special clinical populations including renal transplant patients, hepatocellular carcinoma (HCC) patients, liver disease patients, and patients with psoriasis, among others. This latter category represents patients with clinical conditions associated with HCV infection or patients with specific diseases that require clinical care, and thus can be exposed to HCV in medical care facilities. These populations were grouped together as special clinical populations since the level of exposure to HCV is uncertain, and accordingly, it is difficult to categorize them among any of the other three population groups.

Quantitative Analysis {#sec011}
---------------------

Pooled estimates for HCV prevalence among the general population were calculated for Algeria, Morocco and Tunisia since we had a sufficient number of studies to power a meta-analysis in each of these countries. The analysis was conducted using Stata/SEv13 and R2.15.3. Estimates were pooled using a DerSimonian-Laird random effects model which assumes that the true effect size could vary from study to study, and that the true effects are normally distributed \[[@pone.0121873.ref009]\]. The model therefore accounts for both sampling variation and heterogeneity in effect size. Individual studies' effect sizes were weighted using their inverse variance. The variance of the raw proportions was stabilized by transforming the proportions using the Freeman-Tukey type double-arcsine square-root transformation \[[@pone.0121873.ref010]\]. The back-transformed pooled proportions were then calculated using Miller's inverse transformation with the harmonic mean of the sample sizes \[[@pone.0121873.ref011]\]. To examine the magnitude of the variation between studies due to heterogeneity rather than chance, we quantified the heterogeneity using the I^2^ measure and its confidence interval \[[@pone.0121873.ref012]\]. We considered a two-sided probability value \<0.10 as significant.

A meta-analysis was not performed for each of Libya and Mauritania. While Libya presented various studies estimating the prevalence of HCV in the general population; the best estimate was chosen as that reported through the Libyan National Survey \[[@pone.0121873.ref013]\] due to its nationally representative sampling technique and large sample size (n = 65,711). Only one study was identified in Mauritania and therefore a meta-analysis was not possible.

Results {#sec012}
=======

Search Results {#sec013}
--------------

A schematic diagram of the selection process is outlined in [Fig. 1](#pone.0121873.g001){ref-type="fig"}, adapted from the PRISMA 2009 flow diagram \[[@pone.0121873.ref006]\]. We identified a total of 1,532 records (585 through PubMed and 947 through Embase) as of December 11, 2013. Of these records, 502 duplicates were identified and excluded. Screening of the remaining titles and abstracts yielded 177 potentially relevant articles. Full-text records of those were retrieved and screened with the exception of four articles for which the full-text could not be retrieved and the abstracts did not report the relevant outcome. Screening of full-texts identified 77 articles for inclusion in the review. Four additional records were identified through screening of bibliographies of reviews; however, they were subsequently excluded as their full-texts could not be retrieved or they were a duplicate for a study already included. An additional 11 relevant records were included through the MENA HIV/AIDS Synthesis Project database (one international organization report and 10 country-level reports).

![Flow chart of article selection adapted from the PRISMA 2009 guidelines \[[@pone.0121873.ref006]\].](pone.0121873.g001){#pone.0121873.g001}

HCV Prevalence Overview {#sec014}
-----------------------

Data on HCV prevalence as well as other indicators were abstracted from the 88 relevant records, and presented in [Table 1](#pone.0121873.t001){ref-type="table"}. In total, 133 HCV prevalence measures were identified by our study. Most reports presenting HCV prevalence in the Maghreb were from Morocco (n = 38) and Tunisia (n = 60). Populations studied to estimate HCV prevalence ranged from general population groups such as blood donors, pregnant women, and healthy adults, to high risk groups such as PWID, dialysis patients, hemophiliacs, and multi-transfused patients. The following is a synthesis of HCV prevalence in each of the Maghreb countries:

10.1371/journal.pone.0121873.t001

###### Studies reporting hepatitis C virus (HCV) prevalence in the Maghreb countries.

![](pone.0121873.t001){#pone.0121873.t001g}

  Citation                                                                                                         Year of Data Collection   Study Site                           Study Design         Population                                                                   Sample Size   Antibody prevalence   RNA Prevalence among Anti-HCV Positive
  ---------------------------------------------------------------------------------------------------------------- ------------------------- ------------------------------------ -------------------- ---------------------------------------------------------------------------- ------------- --------------------- ----------------------------------------
  **ALGERIA**                                                                                                                                                                                                                                                                                                           
  **High Risk**                                                                                                                                                                                                                                                                                                         
  Saidane,11 \[[@pone.0121873.ref014]\]                                                                            2010--2011                Hospital                             CS                   Hemophiliacs                                                                 64            30%                   
  **General Population**                                                                                                                                                                                                                                                                                                
  Aidaoui,08 \[[@pone.0121873.ref015]\]                                                                            2008                      Hospital                             CS                   Pregnant women                                                               3044          0.63%                 
  Ayed, 95 \[[@pone.0121873.ref016]\]                                                                              1992--1993                Hospital                                                  Pregnant women                                                               715           0.19%                 
  Ayed, 95 \[[@pone.0121873.ref016]\]                                                                              1992--1993                Blood transfusion center             CS                   Blood donors                                                                 1112          0.18%                 
  **LIBYA**                                                                                                                                                                                                                                                                                                             
  **High Risk**                                                                                                                                                                                                                                                                                                         
  Mirzoyan,13 \[[@pone.0121873.ref017]\]                                                                           2010                                                           CS                   People who inject drugs                                                      328           94.2%                 
  Yerly,01 \[[@pone.0121873.ref018]\]                                                                              1998--1999                Hospital                             CS                   HIV patients (children) suspected of acquiring infection paranterally        111           46%                   
  Yerly,01 \[[@pone.0121873.ref018]\]                                                                              1998--1999                Hospital                             CS                   HIV patients (children) suspected of acquiring infection paranterally        37            43%                   
  Elzouki,93 \[[@pone.0121873.ref019]\]                                                                                                      Hospital                             CS                   Dialysis patients                                                            47            42.5%                 
  Alashek,12 \[[@pone.0121873.ref020]\]                                                                            2009--2010                Hemodialysis centers                 CS                   Dialysis patients                                                            2382          32.3%                 
  Elzouki,95 \[[@pone.0121873.ref021]\]                                                                                                      Hospital                             CS                   Dialysis patients                                                            153           21%                   72%
  Daw,02 \[[@pone.0121873.ref022]\]                                                                                1999--2001                                                     CS                   Dialysis patients                                                            200           20.5%                 
  Daw,02 \[[@pone.0121873.ref022]\]                                                                                1999--2001                                                                          Multi-transfused patients                                                    250           10.8%                 
  **Intermediate Risk**                                                                                                                                                                                                                                                                                                 
  Yerly,01 \[[@pone.0121873.ref018]\]                                                                              1998--1999                Hospital                             CS                   Parents of children with HIV suspected of acquiring infection paranterally   46            4.35%                 
  Kutrani,07 \[[@pone.0121873.ref023]\]                                                                            2003                      Hospital                             CS                   Non-Libyan patients referred to the infectious disease department            281           54.09%                
  Kutrani,07 \[[@pone.0121873.ref023]\]                                                                            2003                      Hospital                             CS                   Libyan patients referred to the infectious disease department                1019          44.95%                
  Alashek,10 \[[@pone.0121873.ref024]\]                                                                            2009                      Dialysis units                       CS                   Diabetic patients                                                            749           24.4%                 
  Ziglam,12 \[[@pone.0121873.ref025]\]                                                                             2006                      Prisons                              CS                   Prisoners                                                                    6371          23.7%                 
  Valadez,13 \[[@pone.0121873.ref026]\]                                                                            2010--2011                Community probability based sample   CS                   Male sex workers                                                             227           7.3%                  
  Saleh,94 \[[@pone.0121873.ref027]\]                                                                              1992                      Hospital                             CS                   Hospital workers                                                             190           6.8%                  69.23%
  Valadez,13 \[[@pone.0121873.ref026]\]                                                                            2010--2011                Community probability based sample   CS                   Female sex workers                                                           69            5.2%                  
  Abddulsalam Bagar,10 \[[@pone.0121873.ref028]\]                                                                  2007--2008                Hospital                             CS (Retrospective)   Patients with unspecified disease                                            17419         3.67%                 
  Franka,09 \[[@pone.0121873.ref029]\]                                                                             2004                      Hospital                             CS                   Medical waste handlers                                                       300           2.7%                  
  Daw,02 \[[@pone.0121873.ref022]\]                                                                                1999--2001                                                     CS                   Hospital workers                                                             459           2.0%                  
  Franka,09 \[[@pone.0121873.ref029]\]                                                                             2004                      Medical management facility          CS                   Non-medical waste handlers                                                   300           0%                    
  **General Population**                                                                                                                                                                                                                                                                                                
  Shabash,10 \[[@pone.0121873.ref030]\]                                                                                                                                                                General population                                                           878           23.2%                 
  Saleh,94 \[[@pone.0121873.ref027]\]                                                                              1992                      Hospital                             CS                   Blood donors                                                                 76            6.6%                  60%
  Shabash,10 \[[@pone.0121873.ref031]\]                                                                            2003--2008                Laboratory                           CS (Retrospective)   General population                                                           1008214       1.77%                 
  Daw,02 \[[@pone.0121873.ref022]\]                                                                                1999--2001                                                     CS                   Healthy adults                                                               800           1.6%                  
  Daw,02 \[[@pone.0121873.ref022]\]                                                                                1999--2001                                                     CS                   Blood donors                                                                 1200          1.2%                  
  Daw,14 \[[@pone.0121873.ref013]\]                                                                                2008                      Libyan national survey               CS                   General population                                                           65711         1.19%                 
  Elzouki,95 \[[@pone.0121873.ref032]\]                                                                                                      Blood Bank                           CS                   Blood donors                                                                 86            0.9%                  
  **Special Clinical Population**                                                                                                                                                                                                                                                                                       
  Elbouaishi,10 \[[@pone.0121873.ref033]\]                                                                                                   Hospital                             CS (Retrospective)   Nephrotic syndrome patients (children)                                       329           8.51%                 
  **MAURITANIA**                                                                                                                                                                                                                                                                                                        
  **General Population**                                                                                                                                                                                                                                                                                                
  Lo,99 \[[@pone.0121873.ref034]\]                                                                                 1998                      Hospital                             CS                   Blood donors                                                                 349           1.1%                  
  **MOROCCO**                                                                                                                                                                                                                                                                                                           
  **High Risk**                                                                                                                                                                                                                                                                                                         
  HIV Integrated Behavioral and Biological Surveillance Survey,12 \[[@pone.0121873.ref035]\]                       2011--2012                                                     CS                   People who inject drugs                                                      274           79.2%                 
  Boulaajaj,05 \[[@pone.0121873.ref036]\]                                                                          1983--2002                Hospital                             CS (Retrospective)   Dialysis patients                                                            126           76%                   
  Sekkat,08 \[[@pone.0121873.ref037]\]                                                                             2003--2004                Dialysis units                       CS                   Dialysis Patients                                                            303           68.3%                 
  Amar,05 \[[@pone.0121873.ref038]\]                                                                                                         Dialysis units                       CS                   Dialysis patients                                                            85            54.12%                
  HIV Integrated Behavioral and Biological Surveillance Survey,12 \[[@pone.0121873.ref035]\]                       2010--2011                                                     CS                   People who inject drugs                                                      261           45.6%                 
  Benjelloun,96 \[[@pone.0121873.ref039]\]                                                                                                   Hemophilia treatment center          CS                   Hemophiliacs                                                                 118           42.4%                 
  Bousfiha,99 \[[@pone.0121873.ref040]\]                                                                           1999                      Hemophilia treatment center          CS                   Hemophiliacs (children)                                                      39            41%                   
  Benjelloun,96 \[[@pone.0121873.ref039]\]                                                                                                   Dialysis units                       CS                   Dialysis patients                                                            114           35.1%                 
  HIV Integrated Behavioral and Biological Surveillance Survey,12 \[[@pone.0121873.ref035]\]                       2010--2011                                                     CS                   People who inject drugs                                                      22            31.8%                 
  HIV Integrated Behavioral and Biological Surveillance Survey,12 \[[@pone.0121873.ref035]\]                       2011--2012                                                     CS                   People who inject drugs                                                      83            22.9%                 
  El Khorassani,10 \[[@pone.0121873.ref041]\]                                                                      1981--2006                Hospital                             CS (Retrospective)   Hemophiliacs                                                                 262           2.29%                 
  **Intermediate Risk**                                                                                                                                                                                                                                                                                                 
  Benjelloun,96\[[@pone.0121873.ref039]\]                                                                                                    STD center                           CS                   HIV patients                                                                 116           19.8%                 
  Cacoub,00 \[[@pone.0121873.ref042]\]                                                                             1995--1996                Hospital                             CS                   Inpatients                                                                   280           10.36%                75%
  Cacoub,00 \[[@pone.0121873.ref042]\]                                                                             1995--1996                Hospital                             CS                   Outpatients                                                                  503           6.16%                 
  Rebbani,13 \[[@pone.0121873.ref043]\]                                                                            2006--2010                Infectious disease center            CS                   HIV patients                                                                 503           5.4%                  
  Zahraoui-Mehadji,04 \[[@pone.0121873.ref044]\]                                                                   2001                                                           CS                   Traditional barbers                                                          150           5%                    
  Benjelloun,96\[[@pone.0121873.ref039]\]                                                                                                    STD center                           CS                   STD patients                                                                 2088          3%                    
  Belbacha,11 \[[@pone.0121873.ref045]\]                                                                           2007                                                           CS                   Traditional barbers                                                          267           1.10%                 
  Lahlou Amine,10 \[[@pone.0121873.ref046]\]                                                                       2005--2006                Hospital                             CS (Retrospective)   Inpatients                                                                   2350          0.76%                 
  **General Population**                                                                                                                                                                                                                                                                                                
  Benouda,09 \[[@pone.0121873.ref047]\]                                                                            2005--2007                Laboratory                           CS                   General population                                                           8326          1.93%                 
  Baha,13 \[[@pone.0121873.ref048]\]                                                                               2005--2011                Nationwide                           CS                   General population                                                           41269         1.58%                 
  Belbacha,11 \[[@pone.0121873.ref045]\]                                                                           2007                                                                                Clients of barbers                                                           529           1.30%                 
  Benani,11 \[[@pone.0121873.ref049]\]                                                                                                                                            CS                   General population                                                           24646         1.10%                 
  Benjelloun,96 \[[@pone.0121873.ref039]\]                                                                                                   Blood transfusion center             CS                   Blood donors                                                                 1000          1.1%                  
  Benjelloun,96 \[[@pone.0121873.ref039]\]                                                                                                   Hospital                             CS                   Pregnant women                                                               676           1.0%                  
  Aqodad,11 \[[@pone.0121873.ref050]\]                                                                             2006--2007                Blood bank                           CS                   Blood donors                                                                 777           0.8%                  
  Baha,13 \[[@pone.0121873.ref048]\]                                                                               2005--2011                Blood transfusion center             CS                   Blood donors                                                                 169605        0.62%                 
  Regional Database on HIV/AIDS. WHO Regional Office for the Eastern Mediterranean,11 \[[@pone.0121873.ref051]\]                                                                  CS                   ANC and family planning clinic attendees                                                   0.5%                  
  Lahlou Amine,11 \[[@pone.0121873.ref046]\]                                                                       2005--2006                Hospital                             CS (Retrospective)   Army recruits                                                                16000         0.35%                 
  Zohoun,11 \[[@pone.0121873.ref052]\]                                                                             2008--2009                Hospital                             CS (Retrospective)   Blood donors                                                                 19801         0.2%                  
  Regional Database on HIV/AIDS WHO Regional Office for the Eastern Mediterranean,11 \[[@pone.0121873.ref053]\]    2010                                                           CS                   Blood donors                                                                 132197        0.16%                 
  **Special Clinical Population**                                                                                                                                                                                                                                                                                       
  Rioche,91 \[[@pone.0121873.ref054]\]                                                                             1983--1986                Dialysis units                       CS                   Non-A and Non-B chronic hepatitis patients                                   38            73.7%                 
  Ezzikouri,09 \[[@pone.0121873.ref055]\]                                                                          2003--2006                Hospital                             CC                   Hepatocellular carcinoma patients                                            96            57.3%                 
  Rioche,91 \[[@pone.0121873.ref054]\]                                                                             1983--1986                Hospital                             CS                   Non-A and Non-B acute hepatitis patients                                     90            44.4%                 
  Lakhoua Gorgi,10 \[[@pone.0121873.ref056]\]                                                                      1987--2004                Hospital                             CS                   Renal transplant patients                                                    57            19.3%                 
  Radoui,10 \[[@pone.0121873.ref057]\]                                                                             1998--2008                Hospital                             CS                   Renal transplant patients                                                    69            10.1%                 
  Mohammed,12 \[[@pone.0121873.ref058]\]                                                                           2005--2011                Hospital                             CS (Retrospective)   Hepatic steatosis patients                                                   79            3.8%                  
  Lahlou Amine,10 \[[@pone.0121873.ref046]\]                                                                       2005--2006                Hospital                             CS (Retrospective)   Patients consulting for HCV infection                                        7050          2.32%                 
  Bousfiha,99 \[[@pone.0121873.ref059]\]                                                                           1999                      Hospital                             CS                   Acute hepatitis patients (children)                                          130           0%                    
  **TUNISIA**                                                                                                                                                                                                                                                                                                           
  **High Risk**                                                                                                                                                                                                                                                                                                         
  Ayed,03 \[[@pone.0121873.ref060]\]                                                                               2001                      Dialysis units/Overall               CS                   Dialysis patients                                                            1394          22.24%                76.7%
  Belarbi,13 \[[@pone.0121873.ref061]\]                                                                            2012                      Outpatient hospital                  CS (Retrospective)   People who inject drugs                                                      23            21.7%                 
  Ayed,03 \[[@pone.0121873.ref060]\]                                                                               2001                      Dialysis units/Central                                                                                                                 1314          18.47%                60.5%
  Ayed,03 \[[@pone.0121873.ref060]\]                                                                               2001                      Dialysis units/Northwest                                                                                                               358           15.36%                70.9%
  Ayed,03 \[[@pone.0121873.ref060]\]                                                                               2001                      Dialysis units/Northern                                                                                                                279           15.7%                 90.9%
  Ayed,03 \[[@pone.0121873.ref060]\]                                                                               2001                      Dialysis units/Southern                                                                                                                796           14.57%                71.5%
  Bejaoui,13 \[[@pone.0121873.ref062]\]                                                                                                      Medical institutions                 CS (Retrospective)   Thalassemia patients                                                         391           6.1%                  
  Hannachi,11 \[[@pone.0121873.ref063]\]                                                                           2008--2009                Hospital                             CC                   Multi-transfused patients                                                    107           4.7%                  
  Tunisia Ministry of Health,10 \[[@pone.0121873.ref064]\]                                                         2009                                                           CS                   People who inject drugs                                                      715           29.1%                 
  Djebbi,08 \[[@pone.0121873.ref065]\]                                                                             2003                      Hospital                             CS                   Hemophiliacs                                                                 95            50.5%                 87.5%
  Sassi,00 \[[@pone.0121873.ref066]\]                                                                                                        Dialysis units                       CS                   Dialysis patients                                                            58            46.5%                 51%
  Hmida,95 \[[@pone.0121873.ref067]\]                                                                                                        Dialysis units                       CS                   Dialysis patients                                                            235           45.1%                 
  Ben Othman,04 \[[@pone.0121873.ref068]\]                                                                         2000--2002                Dialysis units                       CS                   Dialysis patients                                                            276           32.6%                 78.89%
  Ayed,03 \[[@pone.0121873.ref060]\]                                                                               2001                      Dialysis units/Northeastern                                                                                                            199           30.15%                93.33%
  Hachicha,95 \[[@pone.0121873.ref069]\]                                                                                                     Dialysis units                       CS                   Dialysis patients                                                            235           42%                   
  Hmaied,06 \[[@pone.0121873.ref070]\]                                                                             2001--2003                Dialysis units                       CS                   Dialysis patients                                                            395           20%                   73%
  Jemni,94 \[[@pone.0121873.ref071]\]                                                                                                        Dialysis units                       CS                   Dialysis patients                                                            63            42%                   
  Langar,05 \[[@pone.0121873.ref072]\]                                                                                                       Hospital                             CS                   Hemophiliacs                                                                 70            50%                   
  **Intermediate Risk**                                                                                                                                                                                                                                                                                                 
  Kilani,07 \[[@pone.0121873.ref073]\]                                                                             1997--2005                Hospital                             CS                   HIV patients                                                                 362           39.7%                 
  Maaref,11 \[[@pone.0121873.ref074]\]                                                                             2006                      Hospital                             CS                   HIV patients                                                                 125           26.4%                 
  Larabi,01 \[[@pone.0121873.ref075]\]                                                                             1997--1999                Hospital                             CS                   Inpatients                                                                   542           20.3%                 
  Kaabia,09 \[[@pone.0121873.ref076]\]                                                                             2003                      Hospital                             CS                   Diabetic patients                                                            1269          1.3%                  
  Znazen,10 \[[@pone.0121873.ref077]\]                                                                             2007                      Hospital                             CS                   Female sex workers                                                           188           1.1%                  
  Kaabia,09 \[[@pone.0121873.ref078]\]                                                                             2005                      Hospital                             CS                   Hospital workers                                                             885           1%                    
  **General Population**                                                                                                                                                                                                                                                                                                
  Coursaget,90 \[[@pone.0121873.ref079]\]                                                                          1982--1986                                                     CS                   Blood donors                                                                 99            3.0%                  
  Coursaget,95 \[[@pone.0121873.ref080]\]                                                                                                    Hospital                             CS                   Blood donors                                                                 45            2.2%                  
  Krichen,01 \[[@pone.0121873.ref081]\]                                                                            1995--1997                                                     CS                   Blood donors                                                                 42623         1.71%                 
  Mejri,05 \[[@pone.0121873.ref082]\]                                                                              1996                      Households                           CS                   General population                                                           4157          1.7%                  82%
  Larabi,01 \[[@pone.0121873.ref075]\]                                                                             1997--1999                Hospital                             CS                   Blood donors                                                                 3480          1.18%                 
  Slama,91 \[[@pone.0121873.ref083]\]                                                                                                        Secondary schools                    CS                   Blood donors                                                                 2006          1.09%                 
  HIV/AIDS Quarterly Report,07 \[[@pone.0121873.ref084]\]                                                          2007- 2^nd^ Quarter                                            CS                                                                                                24247         0.87%                 
  Gorgi,98 \[[@pone.0121873.ref085]\]                                                                              1994--1996                Community                            CS                   General population                                                           3079          0.71%                 
  HIV/AIDS Quarterly Report,07 \[[@pone.0121873.ref084]\]                                                          2007- 3^rd^ Quarter                                            CS                                                                                                10526         0.64%                 
  Hannachi,11 \[[@pone.0121873.ref063]\]                                                                           2008--2009                Hospital                             CC                   Controls of a case-control study                                             160           0.6%                  
  Kaabia,09 \[[@pone.0121873.ref076]\]                                                                             2003                      Hospital                             CS                   Controls of a case-control study                                             1315          0.6%                  
  Hatira,00 \[[@pone.0121873.ref086]\]                                                                             1994--1997                Blood bank                           CS                   Blood donors                                                                 34130         0.56%                 
  HIV/AIDS Quarterly Report,06 \[[@pone.0121873.ref087]\]                                                          2006- 3^rd^ Quarter                                            CS                                                                                                20803         0.54%                 
  Triki,94 \[[@pone.0121873.ref088]\]                                                                                                        Laboratory                           CS                   Healthy adults                                                               735           0.40%                 
  Triki,97 \[[@pone.0121873.ref089]\]                                                                              1987--1994                                                     CS                   Blood donors                                                                 785           0.4%                  
  HIV/AIDS Quarterly Report,07 \[[@pone.0121873.ref084]\]                                                          2007- 4^th^ Quarter                                            CS                                                                                                58368         0.36%                 
  HIV/AIDS Quarterly Report,06 \[[@pone.0121873.ref087]\]                                                          2006- 2^nd^ Quarter                                            CS                   Blood donors                                                                 31115         0.34%                 
  Kallel,11 \[[@pone.0121873.ref090]\]                                                                                                                                            CC                   Controls of a case-control study                                             300           0.33%                 
  HIV/AIDS Quarterly Report,06 \[[@pone.0121873.ref087]\]                                                          2006- 4^th^ Quarter                                            CS                                                                                                28428         0.30%                 
  HIV/AIDS Quarterly Report,07 \[[@pone.0121873.ref084]\]                                                          2007- 1^st^ Quarter                                            CS                                                                                                259890        0.26%                 
  Hannachi,11 \[[@pone.0121873.ref091]\]                                                                           2006                      Hospital                             CS                   Pregnant women                                                               404           0.2%                  
  Mejri,05 \[[@pone.0121873.ref082]\]                                                                              1996                      Households                           CS                   General population                                                           7350          0.2%                  71%
  Abid,97 \[[@pone.0121873.ref092]\]                                                                               1994                      Blood bank                           CS                   Blood donors                                                                 43000         0.18%                 
  Mahjoub,13 \[[@pone.0121873.ref093]\]                                                                            2000--2010                                                     CS                   Blood donors (military)                                                      182996        0.14%                 
  Samoud,11 \[[@pone.0121873.ref094]\]                                                                                                                                            CC                   Healthy adults                                                               64            0%                    
  **Special Clinical Populations**                                                                                                                                                                                                                                                                                      
  Bouzgarrou,11 \[[@pone.0121873.ref095]\]                                                                         2005--2008                Hospital                             CS                   Chronic hepatitis patients                                                   77            80.52%                
  Coursaget,90\[[@pone.0121873.ref079]\]                                                                           1982--1986                                                     CS                   Non-A and Non-B acute hepatitis patients                                     25            48.0%                 
  Triki,94 \[[@pone.0121873.ref088]\]                                                                                                        Laboratory                           CS                   Cirrhosis patients                                                           168           43%                   
  Coursaget,92 \[[@pone.0121873.ref096]\]                                                                                                                                         CS                   Cirrhosis patients                                                           23            31%                   
  Lakhoua Gorgi,10 \[[@pone.0121873.ref056]\]                                                                      1987--2004                Hospital                             CS                   Renal transplant patients                                                    115           20.9%                 91.7%
  Triki,94 \[[@pone.0121873.ref088]\]                                                                                                        Laboratory                           CS                   Hepatocellular carcinoma patients                                            31            19%                   
  Coursaget,95 \[[@pone.0121873.ref080]\]                                                                                                    Hospital                             CS                   Acute hepatitis patients                                                     45            18%                   
  Coursaget,90\[[@pone.0121873.ref079]\]                                                                           1982--1986                                                     CS                   HBV patients                                                                 28            14.3%                 
  Samoud,11 \[[@pone.0121873.ref094]\]                                                                                                                                            CC                   Psoriatic patients                                                           41            9.75%                 
  Coursaget,92 \[[@pone.0121873.ref096]\]                                                                                                                                         CS                   Acute hepatitis patients                                                     25            8%                    
  Hannachi,10 \[[@pone.0121873.ref097]\]                                                                           2010                                                           CS                   HBV patients                                                                 273           3.8%                  
  Kallel,11 \[[@pone.0121873.ref090]\]                                                                                                                                            CC                   Inflammatory bowel disease patients                                          150           2%                    
  **ALGERIA, MOROCCO and TUNISIA**                                                                                                                                                                                                                                                                                      
  **General Population**                                                                                                                                                                                                                                                                                                
  Bahri,11 \[[@pone.0121873.ref098]\]                                                                              2002--2005                Multi-center study                   CC                   Controls of a case-control study                                             250           4.40%                 

CS: cross-sectional study design, CC: case-control study design, STD: sexually transmitted disease, HBV: hepatitis B virus

Note: Citations are sorted within each risk group in descending order of prevalence.

### Algeria {#sec015}

The single study from Algeria reporting on a high risk group examined hemophiliacs, reporting a prevalence of 30% \[[@pone.0121873.ref014]\] ([Table 1](#pone.0121873.t001){ref-type="table"}). Three studies reported general population HCV prevalence estimates in Algeria. Prevalence of 0.6% \[[@pone.0121873.ref015]\] and 0.2% \[[@pone.0121873.ref016]\] was reported among pregnant women, and HCV prevalence of 0.2% \[[@pone.0121873.ref016]\] was reported among blood donors.

### Libya {#sec016}

Among high risk groups in Libya, PWID were reported to have the highest HCV prevalence at 94% \[[@pone.0121873.ref017]\] ([Table 1](#pone.0121873.t001){ref-type="table"}). Dialysis patients had a prevalence ranging from 21% \[[@pone.0121873.ref022]\] to 43% \[[@pone.0121873.ref019]\]. One study examined the prevalence among children infected with HIV and children with HIV who were referred to a specific hospital (both children groups were suspected to have had parenteral exposure to HIV) \[[@pone.0121873.ref018]\]. HCV prevalence was 46% and 43%, respectively \[[@pone.0121873.ref018]\]. Among the parents of the children with HIV who were referred to this specific hospital, HCV prevalence was 4% \[[@pone.0121873.ref018]\].

HCV was measured among several populations at intermediate risk including diabetics (24%) \[[@pone.0121873.ref024]\], prisoners (24%) \[[@pone.0121873.ref025]\], male sex workers (7%) \[[@pone.0121873.ref026]\], female sex workers (5%) \[[@pone.0121873.ref026]\], hospital care workers (2%) \[[@pone.0121873.ref022]\], and medical (3%) and non-medical (0%) waste handlers \[[@pone.0121873.ref029]\] ([Table 1](#pone.0121873.t001){ref-type="table"}). Among patients referred to an infectious disease department, with no further specification, persons of non-Libyan backgrounds had an HCV prevalence of 54% while their Libyan counterparts had a prevalence of 45% \[[@pone.0121873.ref023]\].

Five reports and one national survey reported HCV prevalence among the general population in Libya \[[@pone.0121873.ref013], [@pone.0121873.ref022], [@pone.0121873.ref027], [@pone.0121873.ref030]--[@pone.0121873.ref032]\]. Estimates hovered around 1--2% with two outliers of much larger prevalence ([Table 1](#pone.0121873.t001){ref-type="table"}).

Only one study was conducted among special clinical populations in Libya ([Table 1](#pone.0121873.t001){ref-type="table"}). The study reported HCV prevalence of 9% among children with nephrotic syndrome \[[@pone.0121873.ref033]\].

### Mauritania {#sec017}

Only one study measured HCV prevalence in Mauritania. The study tested 349 blood donors at a national hospital, reporting a prevalence of 1% \[[@pone.0121873.ref034]\]. The majority of donors were males (333 vs. 16).

### Morocco {#sec018}

Among high risk groups, HCV prevalence was measured among PWID, but through small samples, at 32% in Nador and 23% in Tanger \[[@pone.0121873.ref035]\] ([Table 1](#pone.0121873.t001){ref-type="table"}). However, more recently, it was measured among PWID in the same cities, using large probability-based samples (respondent-driven sampling), to be 79% in Nador and 46% in Tanger \[[@pone.0121873.ref035]\]. Among dialysis patients, HCV prevalence ranged from 35% \[[@pone.0121873.ref039]\] to as high as 76% \[[@pone.0121873.ref036]\]. Hemophiliacs had variable rates as reported from three studies with one examining rates in children. At 42%, the earliest of the three studies reported the highest HCV prevalence among hemophiliacs in Morocco \[[@pone.0121873.ref039]\]. The second study, conducted among children, reported a comparable prevalence of 41% \[[@pone.0121873.ref040]\]. The third, and most recent study, reported the lowest HCV prevalence among hemophiliacs at 2% \[[@pone.0121873.ref041]\].

Benjelloun *et al*. examined HCV prevalence among two intermediate risk populations including those having a history of a sexually transmitted disease (STD) and those infected with HIV (likely through a sexual mode of transmission) \[[@pone.0121873.ref039]\]. For those with a history of STD, HCV prevalence was 3%, while for those who tested positive for HIV, HCV prevalence was 20% \[[@pone.0121873.ref039]\]. Another study of HIV infected patients reported an HCV prevalence of 5% \[[@pone.0121873.ref043]\]. Among hospital attendees, an early study reported HCV prevalence of 10% among inpatients and 6% among outpatients \[[@pone.0121873.ref042]\]. A more recent study reported an HCV prevalence of 0.8% among inpatients \[[@pone.0121873.ref046]\]. Traditional barbers were tested for HCV in two studies in Morocco where the prevalence was reported to be 1% \[[@pone.0121873.ref045]\] and 5% \[[@pone.0121873.ref044]\].

Estimates of HCV prevalence in the general population in Morocco came from eight reports including 11 prevalence measures on pregnant women, blood donors, and army recruits, among others. HCV prevalence ranged between 0.2% and 2% ([Table 1](#pone.0121873.t001){ref-type="table"}).

Among special clinical populations, two studies examined HCV prevalence among those who had a renal transplant reporting estimates of 19% \[[@pone.0121873.ref056]\] and 10% \[[@pone.0121873.ref057]\]. HCV prevalence among HCC patients was 57% \[[@pone.0121873.ref055]\]. Individuals with chronic or acute hepatitis had prevalence estimates of 74% and 44% \[[@pone.0121873.ref054]\].

### Tunisia {#sec019}

Among high risk groups, HCV prevalence was measured among PWID to be 22% (small sample) \[[@pone.0121873.ref061]\] and 29% \[[@pone.0121873.ref064]\] ([Table 1](#pone.0121873.t001){ref-type="table"}). Among dialysis patients, several studies reported different measures in different areas which ranged between 15% \[[@pone.0121873.ref060]\] and 47% \[[@pone.0121873.ref066]\]. Djebbi *et al*. and Langar *et al*. measured HCV prevalence among hemophiliacs and reported similar results of 51% \[[@pone.0121873.ref065]\] and 50% \[[@pone.0121873.ref072]\], respectively. HCV prevalence among multi-tranfused patients was 5% \[[@pone.0121873.ref063]\], while it was 6% among thalassemia patients \[[@pone.0121873.ref062]\].

Among intermediate risk populations, HCV prevalence was measured to be 1% among diabetics \[[@pone.0121873.ref076]\], 20% among inpatients and referred patients (non-specified) \[[@pone.0121873.ref075]\], and 1% among hospital employees \[[@pone.0121873.ref078]\]. Among individuals testing positive for HIV, HCV prevalence was 26% \[[@pone.0121873.ref074]\] and 40% \[[@pone.0121873.ref073]\]. Among female sex workers, it was 1% \[[@pone.0121873.ref077]\].

Of the Maghreb countries, Tunisia had the largest number of studies measuring HCV prevalence among general population groups. Many of the studies had large samples (typically over 1,000), and were among populations such as blood donors, pregnant women, and healthy adults, among others. In total, 15 articles and seven country-level reports provided measures for Tunisia's HCV prevalence in the population at large (24 prevalence measures). HCV prevalence in the general population abstracted from these studies ranged between 0% and 3% ([Table 1](#pone.0121873.t001){ref-type="table"}).

Notably, relatively high HCV prevalence was reported among special clinical populations. HCV prevalence ranged between 31% \[[@pone.0121873.ref096]\] and 43% \[[@pone.0121873.ref088]\] among cirrhosis patients, and was as high as 21% \[[@pone.0121873.ref056]\] among renal transplant recipients, and as high as 19% \[[@pone.0121873.ref088]\] among HCC patients. Two studies examining chronic and Non-A and Non-B acute hepatitis reported high HCV prevalence at 81% \[[@pone.0121873.ref095]\] and 48% \[[@pone.0121873.ref079]\], respectively. Two other studies among individuals with acute viral hepatitis estimated HCV prevalence at 8% \[[@pone.0121873.ref096]\] and 18% \[[@pone.0121873.ref080]\].

HCV Incidence Overview {#sec020}
----------------------

Only two studies, both in dialysis units, reported empirical measures of HCV incidence in the Maghreb. The first in Tunisia, by Ben Othman *et al*., reported an HCV incidence rate of 2.8 per 100 person-years in 2000--2002 \[[@pone.0121873.ref068]\]. The second study in Morocco, by Sekkat *et al*., estimated HCV incidence rate at 9.7 per 100 person-years in 2003--2004 \[[@pone.0121873.ref037]\].

Risk Factors {#sec021}
------------

Risk factors were most typically identified in studies conducted among high risk or intermediate risk populations. These included dialysis patients, inpatients, and patients referred to an infectious disease department. Common risk factors identified across countries were the duration of dialysis \[[@pone.0121873.ref021], [@pone.0121873.ref038], [@pone.0121873.ref066]\], history and number of transfusions \[[@pone.0121873.ref038], [@pone.0121873.ref066]\], and whether individuals had a history of surgery or dental work \[[@pone.0121873.ref023], [@pone.0121873.ref042]\].

HCV Genotypes {#sec022}
-------------

Genotype 1 is the most common HCV genotype consistently reported for most countries in the Maghreb \[[@pone.0121873.ref099], [@pone.0121873.ref100]\]. According to a study by Messina *et al*., HCV genotype 1 accounts for 82% of HCV infections in Algeria, 44% of infections in Libya, 74% of infections in Morocco, and 41% of infections in Tunisia \[[@pone.0121873.ref099]\]. Another study by Ezzikouri *et al*. places genotype 4 as the most common genotype in Libya, and genotype 1 as the second most common (genotype 4: 36% vs. genotype 1: 33%) \[[@pone.0121873.ref100]\]. For Algeria, Morocco, and Tunisia, genotype 2 is consistently reported as the second most common genotype \[[@pone.0121873.ref099], [@pone.0121873.ref100]\]. The genotype distribution diversity, as measured by the Shannon Diversity Index, shows high diversity in Libya and Tunisia and low diversity in Algeria and Morocco \[[@pone.0121873.ref099]\]. No data seems to be available for HCV genotype distribution in Mauritania.

National Population-Level HCV Prevalence Estimates {#sec023}
--------------------------------------------------

All individual study estimates for HCV prevalence in the general population are presented in [Fig. 2A](#pone.0121873.g002){ref-type="fig"}. Using these measures, we estimated the national population-level HCV prevalence for each of the five countries ([Fig. 2B](#pone.0121873.g002){ref-type="fig"}). In Libya, since there was a population-based survey, we reported HCV prevalence as measured in this survey, of 1.2% (95% CI: 1.1--1.3) \[[@pone.0121873.ref101]\]. In Mauritania, since there was only one general population study conducted, we reported HCV prevalence in this study, of 1.1% (95% CI: 0--2.3), as an estimate of the national population-level HCV prevalence \[[@pone.0121873.ref034]\].

![Hepatitis C virus (HCV) prevalence in the general population of the Maghreb countries.\
**A.** Available HCV prevalence measures among the general population as abstracted from studies included in the systematic review. **B.** Estimated HCV prevalence at the national level in each of the Maghreb countries.](pone.0121873.g002){#pone.0121873.g002}

[Fig. 3A, 3B, and 3C](#pone.0121873.g003){ref-type="fig"} provide forest plots depicting the specific study estimates as well as the meta-analysis estimates for Algeria, Morocco and Tunisia. The pooled estimate for the national population-level HCV prevalence in Algeria was 0.3% (95% CI 0.1--0.7), I^2^ = 61% (95% CI 0.0--87.7, p = 0.10). The pooled estimate in Morocco was 0.7% (95% CI 0.4--1.1), I^2^ = 99% (95% CI 99.0--99.3, p \< 0.001). The pooled estimate in Tunisia was 0.5% (95% CI 0.3--0.7), I^2^ = 99% (95% CI 98.8--99.1, p \< 0.001).

![Pooled summary estimates of hepatitis C virus (HCV) prevalence among general population groups in A. Algeria; B. Morocco; C. Tunisia.](pone.0121873.g003){#pone.0121873.g003}

Discussion {#sec024}
==========

We provided a comprehensive systematic review and synthesis of HCV prevalence and incidence in the Maghreb countries using a well-defined and thorough methodology and following the PRISMA guidelines. We highlighted the key features of HCV epidemiology in this region and, importantly, estimated the national population-level HCV prevalence in each of the Maghreb countries. With the recent remarkable successes in HCV treatment with direct-acting antivirals \[[@pone.0121873.ref102]--[@pone.0121873.ref105]\], our results take on additional importance as they provide the evidence base necessary for planning of health services, articulation of HCV policy guidelines, and implementation of HCV programming.

Our findings highlight that overall HCV prevalence in the Maghreb countries is at a level of about 1%, comparable to that observed in developed countries \[[@pone.0121873.ref001], [@pone.0121873.ref106]\]. This prevalence level is at odds with that observed in Egypt, the immediate eastern neighbor to the Maghreb, where HCV prevalence is estimated at 15% of the adult population \[[@pone.0121873.ref003], [@pone.0121873.ref004]\]. Additionally, the genotypes most reported in this region vary from that in Egypt (\>95% of infections in Egypt belong to genotype 4) \[[@pone.0121873.ref099]\]. While no genotype information is available for Mauritania, reports from Algeria, Libya, Morocco, and Tunisia suggest genotype 1 as most common \[[@pone.0121873.ref037], [@pone.0121873.ref060], [@pone.0121873.ref099], [@pone.0121873.ref100], [@pone.0121873.ref107]\], in similar pattern to most countries globally \[[@pone.0121873.ref099], [@pone.0121873.ref108]\]. This finding highlights the uniqueness of the Egyptian epidemic and that the major drivers of this epidemic do not appear to be present in North Africa apart from Egypt. It further suggests that the infection transmission networks across the countries of North Africa may not have a sizable overlap.

Nonetheless, there is some evidence that the Egyptian epidemic may have affected HCV patterns in Libya, the neighboring country to the west of Egypt, and possibly Tunisia, the second nearest neighbor to Egypt of the Maghreb countries. HCV genotype 4 appears to account for more than one-third of HCV infections in Libya and one-quarter of infections in Tunisia \[[@pone.0121873.ref022], [@pone.0121873.ref099]\]. This suggests possible cross-over from Egypt into Libya, and then possibly into Tunisia. As many Egyptian migrant workers seek better employment opportunities in Libya, cross border migration may have facilitated avenues for the circulation of HCV from Egypt into Libya. It is possible too that a large fraction of genotype 4 cases in Libya could be reflecting Egyptian migrant workers rather than Libyan nationals. Since genotype 4 is also prevalent in Central Africa \[[@pone.0121873.ref099]\], it is possible that genotype 4 may have circulated into Libya and Tunisia through links to this part of Africa \[[@pone.0121873.ref109]\]. Of note that genotype 4 appears to have very limited presence in Algeria and Morocco \[[@pone.0121873.ref099]\].

Further epidemiological studies are needed to clarify the overlapping chains of transmission across North Africa. Despite the existence of at least some circulation of HCV from Egypt into Libya, the national HCV prevalence in Libya is comparable, though slightly higher, to the rest of the Maghreb countries, and an order of magnitude smaller than that in Egypt \[[@pone.0121873.ref004]\]. This further highlights the uniqueness of the Egyptian epidemic.

Overall, relatively high HCV prevalence levels were documented among individuals in high risk groups. Dialysis patients and transplant recipients, for example, have rates ranging from 16% \[[@pone.0121873.ref060]\] to as high as 76% \[[@pone.0121873.ref036]\]. Studies on HCV incidence among dialysis patients reported high HCV incidence rates of 3 \[[@pone.0121873.ref068]\] and 10 \[[@pone.0121873.ref037]\] per 100 person-years. Additionally, duration of dialysis, number of transfusions, and surgical and dental procedures were consistently cited as major risk factors across studies. HCV prevalence levels remained high in these populations, regardless of year of study, indicating possible ongoing transmission in healthcare settings. These findings suggest that a substantial fraction of HCV infections reflect healthcare-related exposures.

Injecting drug use (IDU) is the largest contributor to current HCV incidence in developed countries \[[@pone.0121873.ref110]\]. However, our findings indicate that this is not necessarily the case in the Maghreb countries. The high HCV prevalence and incidence levels among high risk populations exposed at healthcare facilities ([Table 1](#pone.0121873.t001){ref-type="table"}), such as dialysis patients, suggest that IDU may not be the dominant contributor. Moreover, the prevalence of IDU in the Maghreb countries is lower than global levels, and smaller than that in the eastern part of MENA \[[@pone.0121873.ref111]\]. The prevalence of IDU was estimated at 0.22% in Algeria, 0.14% in Libya, 0.10% in Morocco, and 0.21% in Tunisia \[[@pone.0121873.ref111]\]. These rather low levels, in addition to an overall HCV prevalence of about 50% among PWID in MENA \[[@pone.0121873.ref111]\], suggest that IDU can explain only a minority of prevalent infections. However, given the severity of the HCV and HIV epidemics in Libya among PWID \[[@pone.0121873.ref112]\], it is possible that IDU may play a proportionally larger role in Libya than the rest of the Maghreb countries.

Our results further suggest that other exposures to HCV, in populations at intermediate risk, appear to be present. Much of these seem to be also related to healthcare, as can be seen by the higher HCV prevalence among diabetics, health care workers, and hospitalized populations ([Table 1](#pone.0121873.t001){ref-type="table"}). Prisons appear to be a setting where a significant level of HCV exposure is found ([Table 1](#pone.0121873.t001){ref-type="table"}), probably because of IDU prior to or after incarceration, but also possibly due to tattooing and sharing of utensils in prisons \[[@pone.0121873.ref007], [@pone.0121873.ref111]\]. Some exposures also seem to be related to certain professions or practices, such as among traditional barbers where somewhat considerable HCV prevalence is found ([Table 1](#pone.0121873.t001){ref-type="table"}). It appears also that there is a rather significant HCV prevalence among sexual high risk populations, such as male and female sex workers and STD patients ([Table 1](#pone.0121873.t001){ref-type="table"}). It is not clear though whether these prevalence levels reflect HCV sexual transmission or probably just higher IDU levels among these populations \[[@pone.0121873.ref111], [@pone.0121873.ref113]\].

There is a hint of geographic variability in HCV prevalence between different regions within the same country in both Libya and Tunisia. According to the Libyan population-based survey, HCV prevalence ranged from as low as 0.6% in Misrata to as high as 2.2% in Fezzan \[[@pone.0121873.ref013]\]. Similarly in Tunisia, HCV prevalence was estimated at 0.2% in the south and 1.7% in the northwest \[[@pone.0121873.ref082]\]. Such localized higher HCV prevalence levels have been observed in other settings globally such as in Japan and Taiwan \[[@pone.0121873.ref114]--[@pone.0121873.ref116]\]. They may suggest specific risk factors for HCV exposure at these localities that need to be investigated and identified. It is not clear for example whether such regional variations may reflect variations in infection control measures across the country, say in central health care facilities versus local facilities, or differences in the prevalence of IDU, or possibly the existence of localized traditional medicine practices that may expose individuals to HCV infection such as cautery and skin scarifications. Such factors that can drive geographically different infection transmission patterns appear to be present in MENA \[[@pone.0121873.ref007], [@pone.0121873.ref117]\]. Mapping of HCV exposure spatially, as has been done recently in Egypt \[[@pone.0121873.ref118]\], can shed light on such local risk factors and may point to wider issues of infection control that are beyond HCV concerns.

Our study provided country-specific estimates of HCV prevalence in the Maghreb using systematic review and meta-analysis methodology, a distinct approach from that used by the Global Burden of Disease (GBD) study \[[@pone.0121873.ref001]\]. Our approach is empirically focused whereby data on HCV prevalence are compiled through a systematic methodology and then pooled through formal statistical methods to yield estimates. The GBD approach utilizes mathematical modeling whereby systematically-compiled input data are used to parametrize complex models to generate the estimates. While our country-specific estimates are produced using data only from the respective country, GBD models are parametrized by data from different countries. While the overarching aim of our approach is to delineate the epidemiology of the infection, the GBD's approach aims to reach estimates for the disease burden resulting from complications of this infection. These two approaches therefore should be seen as complementary approaches, each of which has its strengths and limitations, and each of which is informing the other.

Among the limitations of our study are the variability of the number studies across countries and the low number of studies from Algeria and Mauritania (only one study was identified in Mauritania). The general population studies included in the meta-analyses may not have been representative of the population at large. Nearly all studies were on convenient samples and there was only one study on a nationally representative and probability-based sample (in Libya; [Table 1](#pone.0121873.t001){ref-type="table"}). Many of the studies, particularly the large ones, were among blood donors or pregnant women. HCV prevalence in these populations may underestimate HCV prevalence in the whole population; there could be selection towards lower risk among blood donors, and women tend to have lower HCV prevalence than men.

Our meta-analyses highlighted that there is substantial heterogeneity among the studies conducted in general population groups. This is not surprising considering the differences between studies in terms of the specific general population studied, sampling methodology and participant recruitment, age-group representation in the sample, year of study, location and geographic sub-region of study, and assay used. However, due to the small number of observations for each country, we were unable to conduct a meta-regression analysis to identify potential sources of variation to explain the observed heterogeneity for each country.

We classified the populations into high risk, intermediate risk, and general population (low risk) groups by convention in HCV epidemiology literature. However, there is no established existing classification of risk for some populations, and the information available in some studies was not sufficient to determine the level of risk. In these situations the level of risk was determined based on our best judgment of the risk of exposure to HCV infection in this population. For example, HIV infected patients who have acquired HIV likely through a parenteral mode of transmission, were classified as a high risk population, whereas HIV infected persons who have acquired HIV likely though a sexual mode of transmission, were classified as an intermediate risk population. Furthermore, clinical populations for which the risk of exposure was uncertain were classified into an independent category as *special clinical populations*.

Another limitation in our study is that there was variability in the diagnostic assays used across studies. Earlier studies typically reported the use of 1^st^ and 2^nd^ generation ELISA tests, which lack the sensitivity and specificity of the 3^rd^ generation ELISA tests. Such variability in assays may impact the representativeness of earlier studies. Lastly, only two studies in this region provided empirical measures of HCV incidence, and these were fairly dated.

Conclusion {#sec025}
==========

HCV prevalence in the Maghreb region of MENA is comparable to that in developed countries of about 1%. Yet, the evidence synthesized here suggests ongoing HCV transmission through specific high-risk healthcare exposures such as dialysis and blood transfusions. IDU is also a major, though probably not dominant, contributor to HCV transmission in these countries. Other exposures, though at much reduced risk, appear to be related to intermediate-risk healthcare settings or procedures and specific professions or community practices. Further research is needed to draw a more thorough and complete understanding of HCV epidemiology in this part of MENA, especially so in the countries where a limited number of studies have been conducted (Algeria and Mauritania). Our findings suggest the need for a targeted approach to control HCV transmission by focusing the response on the settings of exposure. The findings also provide the evidence base necessary to inform planning of health service provision, articulation of HCV policy guidelines, and implementation of HCV programming to reduce HCV transmission and decrease the burden of its associated diseases.
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